Madrigal Pharmaceuticals Inc. (MDGL) Income Statement Analysis - Revenue, Earnings & Profitability Metrics - Stocknear

Madrigal Pharmaceuticals ...

NASDAQ: MDGL · Real-Time Price · USD
432.89
1.68 (0.39%)
At close: Sep 05, 2025, 3:59 PM
432.89
0.00%
After-hours: Sep 05, 2025, 05:34 PM EDT

Madrigal Pharmaceuticals Income Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Revenue
180.13M n/a n/a n/a
Cost of Revenue
7.33M 527K 467K 405K
Gross Profit
172.8M -527K -467K -405K
Operating Income
-497.88M -380.5M -293.57M -241.98M
Interest Income
46.65M 19.58M 2.19M 363K
Pretax Income
-465.89M -373.63M -295.35M -241.85M
Net Income
-465.89M -373.63M -295.35M -241.85M
Selling & General & Admin
435.06M 108.15M 48.13M 37.32M
Research & Development
236.72M 271.82M 245.44M 205.16M
Other Expenses
n/a n/a n/a n/a
Operating Expenses
670.68M 379.97M 293.1M 241.58M
Interest Expense
14.67M 12.71M 3.96M n/a
Selling & Marketing Expenses
n/a n/a n/a n/a
Cost & Expenses
678.01M 380.5M 293.57M 242.48M
Income Tax Expense
n/a n/a n/a n/a
Shares Outstanding (Basic)
21.27M 18.69M 17.14M 16.54M
Shares Outstanding (Diluted)
21.27M 18.69M 17.14M 16.54M
EPS (Basic)
-21.9 -19.99 -17.23 -14.63
EPS (Diluted)
-21.9 -19.99 -17.23 -14.63
EBITDA
-450.13M -360.39M -290.92M -241.44M
EBIT
-451.22M -360.92M -291.39M -241.85M
Depreciation & Amortization
1.1M 527K 467K 405K